Drug Profile
CV 638
Alternative Names: CV-638Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Finlay Institute of Cuba
- Developer Finlay Vaccine Institute
- Class Antibacterials; Antivirals; Attenuated vaccines; Bacterial vaccines; Cholera vaccines; Hepatitis A vaccines; Malaria vaccines; Meningococcal vaccines; Parasitic vaccines; Pneumococcal vaccines; Tuberculosis vaccines; Viral vaccines
- Mechanism of Action Bacterial capsule modulators; Bacterial outer membrane protein modulators; Bacterial polysaccharide modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cholera
- No development reported Hepatitis A; Malaria; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Pertussis; Pneumococcal infections; Sexually transmitted infections; Tuberculosis
Most Recent Events
- 28 Mar 2023 CV 638 is still in clinical phase for Cholera in unknown location (Finlay Institute of vaccine pipeline, March 2023)
- 28 Mar 2023 Clinical trials in Cholera (Prevention) in Unkown location (unspecified route) (Finlay Institute of vaccine pipeline, March 2023)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Cholera(Prevention) in Cuba (PO, Tablet)